Product Images Oxaliplatin

This is a description for Oxaliplatin Injection, USP indicating that it is a cytotoxic agent used for Intravenous Use Only. The product comes in 1x10 mL Single-dose Vial and each vial contains Oxaliplatin, USP 50g and Water for Injection, USP (10mL). The text also emphasizes DO NOT MIX OR ADD TO SODIUM CHLORIDE CHLORIDE-CONTAINING SOLUTIONS. The package insert provides details on further required dilution. The product should be stored between 20°C to 25°C (68°F to 77°F) and should be protected from light. The text mentions manufacturing information but includes unusual character encoding prohibiting it from being read.*

This is a description of a medication called Oxaliplatin Injection, USP—a cytotoxic agent—used for intravenous use only. It is a sterile aqueous solution with a strength of 100mg/20mL (5mg/mL). The product should not be mixed or added to chloride-containing solutions. The solution is preservative-free, and it comes in a single-dose vial. The users need to read the package insert for required further dilution. It is advised to store the product between 20-25°C (68° to T7°F) and protect it from light. The unused portion must be discarded, and the storage of further diluted solutions must be as per package insert instructions. The product is manufactured by Gland Pharma Limited.*

Oxaliplatin Injection, USP is a cytotoxic agent used for intravenous use only. It comes in a single-dose vial of 40mL, containing Oxaliplatin, USP 200 mg and Water for Injection, USP. The solution is a sterile aqueous solution that is free of preservatives. Oxaliplatin should not be mixed or added to sodium chloride or chloride-containing solutions. The package insert gives further guidance on required dilution. Manufactured by Gland Pharma Limited, it should be stored between 20°C and 25°C, with excursions permitted between 15°C and 30°C. It must not be frozen and should be discarded once ampoule has been opened, and the remaining must be stored according to the package insert.*

This is a graph that shows the survival rate of patients over a period of 28 months. The comparison is made between the group that received laptinib and 5FU/LY to the group that got irinotecan plus SFU/LY. It can be observed that the latter group had a higher survival rate, with the difference being statistically significant (p<0.0001). The data suggests that irinotecan plus SFU/LY may be a more effective treatment for patients.*